Difference between revisions of "Dermagraft-TC"
Jump to navigation
Jump to search
m (remove <coauthors> parameter) |
WikiModEn2 (talk | contribs) (Wikify.) |
||
(5 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
[[Image:Dermagraft.png|right|thumb|]] | [[Image:Dermagraft.png|right|thumb|]] | ||
− | '''Dermagraft-TC''' | + | '''Dermagraft-TC''' is an artifical [[skin]] created from harvested [[foreskin| foreskins]] from infant [[circumcision]].<ref name='Advanced Biohealing, 2010'>{{REFweb |
|quote=Dermagraft is manufactured from human fibroblast cells derived from newborn foreskin tissue. | |quote=Dermagraft is manufactured from human fibroblast cells derived from newborn foreskin tissue. | ||
|url=http://www.dermagraft.com/about/overview/ | |url=http://www.dermagraft.com/about/overview/ | ||
Line 10: | Line 10: | ||
|date= | |date= | ||
|accessdate=2011-03-06 | |accessdate=2011-03-06 | ||
− | }}</ref> It is made and sold by Advanced Tissue Sciences (ATS), which is a corporation based in La Jolla, CA. Dermagraft-TC is [[FDA]] approved,<ref name='MediLexicon 2011-03-06'>{{REFweb | + | }}</ref> It is made and sold by [[Advanced Tissue Sciences]] (ATS), which is a corporation based in La Jolla, CA. Dermagraft-TC is [[FDA]] approved,<ref name='MediLexicon 2011-03-06'>{{REFweb |
− | |quote=...fibroblast-derived temporary skin substitute for the treatment of partial-thickness burns that has been approved for marketing by the FDA. | + | |quote=...fibroblast-derived temporary [[skin]] substitute for the treatment of partial-thickness burns that has been approved for marketing by the FDA. |
|url=http://www.medilexicon.com/drugs/dermagraft-tc.php#GeneralInformation | |url=http://www.medilexicon.com/drugs/dermagraft-tc.php#GeneralInformation | ||
|title=Dermagraft-TC | |title=Dermagraft-TC | ||
Line 27: | Line 27: | ||
|date=2007-03-28 | |date=2007-03-28 | ||
|publisher=Transplant News | |publisher=Transplant News | ||
− | |quote=...the Food and Drug Administration has approved Dermagraft-TC for marketing, making it the first human fibroblast-derived temporary skin substitute to be approved. | + | |quote=...the Food and Drug Administration has approved Dermagraft-TC for marketing, making it the first human fibroblast-derived temporary [[skin]] substitute to be approved. |
|accessdate=2011-03-06 | |accessdate=2011-03-06 | ||
− | }}</ref> and it sells for about $3,000 per square foot; one foreskin contains enough genetic material to grow 250,000 square feet of skin.<ref>{{REFjournal | + | }}</ref> and it sells for about $3,000 per square foot; one foreskin contains enough genetic material to grow 250,000 square feet of [[skin]].<ref>{{REFjournal |
|last=Daecher | |last=Daecher | ||
− | | | + | |init=M |
|title=Circumcision | |title=Circumcision | ||
|journal=Icon | |journal=Icon | ||
Line 48: | Line 48: | ||
{{REF}} | {{REF}} | ||
− | [[Category:Foreskin | + | [[Category:Foreskin product]] |
[[Category:Financial gain]] | [[Category:Financial gain]] | ||
[[Category:From CircLeaks]] | [[Category:From CircLeaks]] | ||
[[Category:From IntactWiki]] | [[Category:From IntactWiki]] | ||
+ | |||
+ | [[de:{{FULLPAGENAME}}]] |
Latest revision as of 20:27, 29 October 2022
Dermagraft-TC is an artifical skin created from harvested foreskins from infant circumcision.[1] It is made and sold by Advanced Tissue Sciences (ATS), which is a corporation based in La Jolla, CA. Dermagraft-TC is FDA approved,[2][3] and it sells for about $3,000 per square foot; one foreskin contains enough genetic material to grow 250,000 square feet of skin.[4]
References
- ↑
Dermagraft-TC: Overview
, Advanced Biohealing, Inc.. Retrieved 6 March 2011.
Quote:Dermagraft is manufactured from human fibroblast cells derived from newborn foreskin tissue.
- ↑
Dermagraft-TC
, MediLexicon. Retrieved 6 March 2011.
Quote:...fibroblast-derived temporary skin substitute for the treatment of partial-thickness burns that has been approved for marketing by the FDA.
- ↑ (28 March 2007)."Advanced Tissue Sciences' temporary wound covering Dermagraft-TC approved for marketing by FDA", Transplant News. Retrieved 6 March 2011.
Quote:...the Food and Drug Administration has approved Dermagraft-TC for marketing, making it the first human fibroblast-derived temporary skin substitute to be approved.
- ↑ Daecher M. Circumcision. Icon. 1998; 2(2): 70-73.